@article{ATM27277,
author = {Aye A. Lwin and Grant R. Pollock and Juan Chipollini},
title = {Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus—trends and effect on overall survival},
journal = {Annals of Translational Medicine},
volume = {7},
number = {Suppl 6},
year = {2019},
keywords = {},
abstract = {Cytoreductive nephrectomy (CN) combined with cytokine therapy was once the standard of care for metastatic renal cell carcinoma (mRCC) (1,2). In the past decade, there have been a myriad of novel therapies in metastatic renal cell carcinoma treatments including targeted therapies such as tyrosine kinase inhibitors (TKIs), mammalian target or rapamycin (mTOR) inhibitors, VEGF inhibitors, and PD-1 inhibitors.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/27277}
}